How Phase 2 Obesity Trial Results At Zealand Pharma (CPSE:ZEAL) Has Changed Its Investment Story

• Zealand Pharma announced Phase 2 ZUPREME-1 data for petrelintide in obesity, published in The Lancet Diabetes & Endocrinology and presented at the 2026 EASD meeting, highlighting weight and cardiometabolic effects with a placebo-controlled design.
• The company is moving petrelintide into a large global Phase 3 program with partner Roche, signalling a shift from an early peptide focus toward broader obesity franchise execution and associated development spend.
• This article examines how Zealand Pharma's investment narrative is being reshaped by Phase 2 petrelintide data as the pipeline advances into Phase 3.

Scan beyond Zealand Pharma and see how other obesity and cardiometabolic players are positioned by reviewing our hand picked 129 healthcare AI stocks in this fast moving corner of healthcare.

Zealand Pharma Investment Narrative Recap

To own Zealand Pharma, you need to believe the obesity and cardiometabolic pipeline can offset pressure on reported earnings, with petrelintide and other late assets eventually supporting a more durable revenue mix. The key near term swing factor remains execution in obesity, both in clinical development and in partnering, while broader biotech volatility and ZEAL’s weak 1 year share return keep sentiment fragile.

The biggest risk still sits with clinical and regulatory outcomes for petrelintide and peers, in a crowded field with heavyweights already entrenched. Recent Phase 2 data publication and Phase 3 initiation sharpen that binary profile rather than changing it, so the overall risk reward balance for Zealand Pharma feels largely intact for now.

The opening of the new Cambridge research hub is the announcement that ties most directly to this shift into a full obesity franchise. Moving its primary US base into a 53,600 RSF facility dedicated to hybrid modalities and automation suggests Zealand Pharma is gearing operations toward faster cycle times from idea to clinic, which matters when competitors iterate quickly.

For you as a shareholder, the hub adds an execution test rather than an instant catalyst. Success means hiring effectively in Massachusetts, integrating advanced modeling into the pipeline, and doing it while R&D spending is already heavy and consensus points to revenue and earnings declines over the next three years. Any slippage here would amplify the existing risk that costs stay ahead of future obesity revenues.

What The Current Zealand Pharma Forecasts Assume

Zealand Pharma's valuation story today leans heavily on numbers that point to a tough revenue outlook in the near term and a compressed profit pool further out. Analysts are modeling revenue to decline by 25.8% a year over the next three years, even as the obesity pipeline moves forward and petrelintide heads into a global Phase 3 effort with Roche.

On earnings, the consensus framework assumes current profit of DKK 2.7 billion trends down to DKK 367.5 million by 2029. That is an earnings drop of about DKK 2.3 billion, not a bump higher. Analysts get there by flexing margins from 59.0% down toward the 19.3% level that reflects the average for US biotech peers, and then applying those margins to the expected future top line rather than projecting a straight-line earnings trajectory from today.

To square those profit assumptions with current share prices, the models then lean on a richer valuation multiple. The implied 2029 P/E of 89.4x on DKK 367.5 million of earnings sits well above the 6.7x multiple applied to current earnings and above the 15.2x sector level cited for US biotechs. For you, that means the story is less about simple growth and more about investors paying a higher price per krone of earnings if obesity assets mature as hoped.

Those same forecasts also incorporate capital structure and discount rate choices that matter for long-term holders of Zealand Pharma. Analyst models assume the share count gradually shrinks, with outstanding shares falling by about 1.27% a year for three years, and they discount future cash flows at roughly 5.8% in order to bring that 2029 picture back to today.

Zealand Pharma's narrative projects DKK 1.9 billion revenue and DKK 367.5 million earnings by 2029. This is based on an assumed 25.8% yearly revenue decline and an earnings decrease of about DKK 2.3 billion from DKK 2.7 billion today.

Discover how Zealand Pharma's fair value indicates a 56% potential upside to its current price that could close more quickly than many investors expect.

Exploring Other Perspectives

One alternate view on Zealand Pharma focuses on the upside if the new Cambridge hub and the obesity franchise scale smoothly. The most optimistic analysts were already pencilling in DKK 4.2b revenue and DKK 435.6m earnings by 2029, with a P/E above 100x. That is a very different story, and this fresh news may lead those opinions to shift again.

Explore 2 other Zealand Pharma fair value estimates, including one that suggests as much as 124% upside from the current price.

Decide For Yourself

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

• A great starting point for your Zealand Pharma research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Zealand Pharma. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Zealand Pharma's overall financial health at a glance.

Looking For More Investment Ideas Beyond Zealand Pharma?

If the Zealand Pharma story has sharpened your thinking about risk, reward and timelines, it can be useful to line it up against a wider watchlist. The Simply Wall St Screener helps you move from a single stock to a shortlist that matches your preferences on quality, valuation and downside protection.

• If you want to focus on financial resilience first and potential upside second, start with a list of solid balance sheet and fundamentals (208 results) that already meet strict balance sheet and fundamentals checks.
• For investors who care most about valuation, use the screener to zero in on 196 high quality undervalued stocks that combine stronger cash flows with what analysts see as relatively low prices.
• If you prefer to hunt for underfollowed opportunities, the screener can surface 615 high quality undiscovered gems that pair robust fundamentals with limited market attention so far.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com